Search Results - "Groenland, S. L."

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer by van Nuland, M., Groenland, S. L., Bergman, A. M., Steeghs, N., Rosing, H., Venekamp, N., Huitema, A. D. R., Beijnen, J. H.

“…Background Abiraterone acetate is an oral 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor approved for the treatment of metastatic castration-resistant prostate…”
Get full text

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study by Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

“…Oral targeted therapies show a high pharmacokinetic (PK) interpatient variability. Even though exposure has been positively correlated with efficacy for many…”
Get full text

Incidence of clinically significant toxicities in patients with high endoxifen concentrations by Groenland, S.L., Sanchez-Spitman, A.B., Moes, D.J.A.R., Koolen, S.L., Dezentjé, V.O., van Erp, N., Mathijssen, R.H.J., Guchelaar, H.-J., Huitema, A.D.R., Steeghs, N.

Get full text

1486PDExposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients by Groenland, S L, Geel, D R, Janssen, J M, Beijnen, J H, Burgers, S A, Smit, E F, Huitema, A D R, Steeghs, N

“…Abstract Background Crizotinib and alectinib are first and second generation ALK-inhibitors, respectively, indicated for the treatment of ALK+ NSCLC. At the…”
Get full text

258PIncidence of clinically significant toxicities in patients with high endoxifen concentrations by Groenland, S L, Sanchez-Spitman, A B, Moes, D J A R, Koolen, S L, Dezentjé, V O, van Erp, N, Mathijssen, R H J, Guchelaar, H-J, Huitema, A D R, Steeghs, N

Get full text

1119PDInducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) by Rischin, D, Groenland, S L, Lim, A M L, Martin-Liberal, J, Moreno, V, Trigo Perez, J M, Le Tourneau, C, Mathew, M, Cho, D C, Hansen, A R, Vincente-Baz, D, Maio, M, Italiano, A, Bauman, J R, Chisamore, M, Zhou, H, Ellis, C, Ballas, M, Hoos, A, Angevin, E

“…Abstract Background INDUCE-1 is a first in human study investigating GSK609 alone (mono) and in combination (combo) with other regimens including pembro. The…”
Get full text

1971PPharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study by Maio, M, Groenland, S L, Bauer, T, Rischin, D, Gardeazabal, I, Moreno, V, Trigo Perez, J M, Chisamore, M, Sadik Shaik, J, Rigat, F, Ellis, C, Chen, H, Gagnon, R, Scherer, S, Turner, D, Yadavilli, S, Ballas, M, Hoos, A, Angevin, E

“…Abstract Background GSK609 an agonist non-T cell depleting IgG4 monoclonal antibody (mAb) against inducible co-stimulatory receptor (ICOS) exhibits T cell…”
Get full text

442OTherapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study by Groenland, S L, Van Eerden, R A G, Koolen, S L, Moes, D J A R, Desar, I M E, Touw, D J, Imholz, A L T, Reyners, A K L, Gelderblom, H, van Erp, N P, Mathijssen, R H J, Huitema, A D R, Steeghs, N

“…Abstract Background Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK). Even though exposure has been linked to efficacy and…”
Get full text